“We think this is the first report of the use of a neoantigen DNA vaccine in a human, and our monitoring confirms the vaccine was successful in prompting an immune response that targeted specific neoantigens in the patient’s tumor,” William Gillanders says.
Researchers have shown that personalized cancer vaccines made using DNA can program the immune system to attack malignant tumors, including breast and pancreatic cancers.
The researchers conducted the study in mice with breast cancer and one patient with late-stage pancreatic cancer.
The COVID-19 vaccines—designed using bits of genetic information that prime our immune systems to recognize and fight off viral infections—have become lifesavers in the global fight to end the pandemic.
Now, the new research has shown that a similar vaccine approach can be used to create personalized vaccines that program the immune system to attack malignant tumors, including breast and pancreatic cancers.
The tailor-made vaccines are designed to target mutated proteins called neoantigens that are unique to a patient’s tumors. Unlike the COVID-19 vaccines made by Moderna and Pfizer/BioNTech that rely on genetic material called mRNA, the personalized cancer vaccines are made using DNA.Continue reading… “DNA-BASED CANCER VACCINE TRIGGERS IMMUNE ATTACK ON TUMORS”